AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ZTS · NYSE · Drug Manufacturers - Specialty & Generic

Zoetis (ZTS)

Develops medicines, vaccines, diagnostics and precision-health tools for pets and livestock.

$71.71

vs last close−1.18 (−1.62%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	2,151	2,213	2,190	2,361	2,388	2,317	2,220	2,460	2,400	2,387	2,262	2,468
Cost of revenue	676	765	680	703	736	741	654	682	715	743	641	673
Gross profit	1,475	1,448	1,510	1,658	1,652	1,576	1,566	1,778	1,685	1,644	1,621	1,795
	677	739	709	752	732	811	720	789	749	818	799	858
Research & development	152	174	162	171	167	186	157	172	170	199	180	173
Selling, general & administrative	525	565	547	581	565	625	563	617	579	619	588	592
Other expenses	0	0	0	0	0	0	0	0	0	0	31	93
Operating income	798	709	801	906	920	765	846	989	936	826	822	937
	−81	−59	−54	−126	−46	−33	−36	−87	−49	−65	−64	−71
Interest income	23	26	32	24	23	27	23	19	26	25	21	0
Interest expense	63	59	62	63	61	56	59	58	64	57	62	61
Other non-operating income	18	0	−8	63	−15	−23	−23	29	−9	8	2	10
Income before tax	717	650	747	780	874	732	810	902	887	761	758	866
Income tax expense	121	127	148	156	182	151	179	184	166	158	157	175
Net income from continuing operations	596	523	599	624	692	581	631	718	721	603	601	691
Other adjustments	0	0	0	0	−10	0	0	0	0	0	0	0
Net income	596	525	599	624	682	581	631	718	721	603	601	691
EPS, basic	$1.29	$1.14	$1.31	$1.37	$1.51	$1.29	$1.41	$1.61	$1.63	$1.38	$1.42	$1.65
EPS, diluted	$1.29	$1.14	$1.31	$1.37	$1.50	$1.29	$1.41	$1.61	$1.63	$1.37	$1.42	$1.65
Weighted average shares, basic	460	459	458	456	453	451	448	445	443	438	422	418
Weighted average shares, diluted	461	460	459	456	454	451	448	446	443	439	422	418
EBITDA	904	835	935	970	1,056	911	988	1,083	1,069	939	939	927
Depreciation & amortization	124	126	126	127	121	123	119	123	124	121	119	0
EBIT	780	709	809	843	935	788	869	960	945	818	820	927